The eight-drug/radiation therapy program (MOPP/ABDV/RT) for advanced Hodgkin's disease. A follow-up report
✍ Scribed by David J. Straus; Jane Myers; Sharon Passe; Charles W. Young; Lourdes Z. Nisce; Burton J. Lee; Benjamin Koziner; Zalmen Arlin; Sanford Kempin; Timothy Gee; Bayard D. Clarkson
- Publisher
- John Wiley and Sons
- Year
- 1980
- Tongue
- English
- Weight
- 829 KB
- Volume
- 46
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Eighty-four evaluable patients with advanced Hodgkin's disease (Stages IIB, IIIA age > 35 or mixed cellularity or lymphocyte depletion histology, IIIB, IVA, and IVB) were treated with alternating monthly MOPP and Adriamycin, bleomycin, dacarbazine, and vinblastine (ABDV). Radiation therapy (RT), 2000 rads in two weeks, was given to areas of initial bulky disease in untreated patients. Complete remission (CR) rates were 80% for previously untreated, 65% for prior RT or minimal chemotherapy treated, and 50% for heavily pretreated patients. Among 49 previously untreated patients there were no primary treatment failures. The estimated two-year relapse rate for the CR group was 9%. The therapeutic effectiveness of this program may have been due to either or both of the following elements:
(1) two non-cross-resistant drug combinations, (2) low dose adjuvant RT to initial sites of bulky disease. These early results are among the best reported for the treatment of advanced Hodgkin's disease.
Cancer 46:233-240, 1980. OMBINATION CHEMOTHERAPY has dramatically C improved the prognosis of patients with advanced Hodgkin's disease. The successful report of Lacher and Durant, who employed vinblastine and chlorambucil in patients relapsing after radiation therapy (RT), encouraged further use of drug combinations in Hodgkin's disease.27 After a successful pilot study at the National Cancer Institute, which used cyclophosphamide, vincristine, methotrexate and p r e d n i s ~n e , ~~ DeVita, Serpick, and Carbone16 devised the MOPP combination (nitrogen mustard, vincristine, procarbazine, and prednisone), which has become the standard treatment for patients with advanced Hodgkin's disease. DeVita et af. achieved an 81% complete remission (CR) rate1"16 and other large studies have reported CR rates varying between 47.5 and 74%.20,22*30339 In DeVita's series, 66% of the complete responders